GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JW Pharmaceutical (XKRX:001065.PFD) » Definitions » Total Equity

JW Pharmaceutical (XKRX:001065.PFD) Total Equity : ₩329,486.74 Mil (As of Dec. 2024)


View and export this data going back to 1976. Start your Free Trial

What is JW Pharmaceutical Total Equity?

JW Pharmaceutical's total equity for the quarter that ended in Dec. 2024 was ₩329,486.74 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

JW Pharmaceutical Total Equity Historical Data

The historical data trend for JW Pharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW Pharmaceutical Total Equity Chart

JW Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 207,466.87 188,539.53 225,759.04 265,440.46 329,486.74

JW Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265,440.46 275,257.08 283,480.30 303,766.50 329,486.74

JW Pharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

JW Pharmaceutical's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=604598.517-275111.775
=329,486.74

JW Pharmaceutical's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=604598.517-275111.775
=329,486.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW Pharmaceutical Total Equity Related Terms

Thank you for viewing the detailed overview of JW Pharmaceutical's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

JW Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JW Pharmaceutical (XKRX:001065.PFD) » Definitions » Total Equity
Comparable Companies
XKRX:220100 XKRX:084110 XKRX:206650 XKRX:170900 XKRX:200670 XKRX:019170 XKRX:176750 XKRX:102940 XKRX:003520 XKRX:000640 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
001067:Korea 001060:Korea
Address
2477, Nambusunhwan-ro, Seocho-gu, KOR
Website
https://www.jw-pharma.co.kr
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.

JW Pharmaceutical Headlines

No Headlines